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Abstract
Group V phospholipase A2 (Pla2g5) is a lipid-generating enzyme necessary for macrophage 
effector functions in pulmonary inflammation. However, the lipid mediators involved and their 
cellular targets have not been identified. Mice lacking Pla2g5 showed markedly reduced lung 
ILC2 activation and eosinophilia following repetitive Alternaria Alternata inhalation. While 
Pla2g5-null mice had Wt levels of immediate IL-33 release after one Alternaria dose, they failed to 
upregulate IL-33 in macrophages following repeated Alternaria administration. Unexpectedly, 
while adoptive transfer of bone marrow-derived (BM)-macrophages restored ILC2 activation and 
eosinophilia in Alternaria-exposed Pla2g5-null mice, exogenous IL-33 did not. Conversely, 
transfers of Pla2g5-null BM-macrophages reduced inflammation in Alternaria-exposed Wt mice. 
Mass spectrometry analysis of free fatty acids (FFAs) demonstrated significantly reduced FFAs 
(including linoleic acid (LA) and oleic acid (OA)) in lung and BM-macrophages lacking Pla2g5. 
Exogenous administration of LA or LA+OA to Wt mice sharply potentiated IL-33-induced lung 
eosinophilia and ILC2 expansion in-vitro and in-vivo. In contrast, OA potentiated IL-33-induced 
inflammation and ILC2 expansion in Pla2g5-null mice, but LA was inactive both in-vivo and in-
vitro. Notably, Pla2g5-null ILC2s showed significantly reduced expression of the FFA-receptor-1 
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compared to Wt ILC2s. Thus, macrophage-associated Pla2g5 contributes significantly to type-2 
immunity through regulation of IL-33 induction and FFA-driven ILC2 activation.
Introduction
Alternaria Alternata is a common fungus that is a source of allergens associated with the 
development of asthma and asthma exacerbations. In mice, Alternaria allergens trigger the 
accumulation of eosinophils and the development of airway hyperreactivity1, 2, each of 
which prominently involves effectors of the innate immune system1, 3, 4. Acute exposure of 
the airways of naive mice to Alternaria causes the rapid release of IL-33 by epithelial cells, 
followed by the activation of group 2 innate lymphoid cells (ILC2s)3, 5. Long-term repetitive 
administration of Alternaria upregulates whole lung expression of IL-33, and promotes 
incremental ILC2-dependent lung eosinophilic inflammation1. ILC2s lack cell surface 
markers associated with major hematopoietic lineages (Lin−)6–8. In the lung they express 
Thy1.2 (CD45+ Lin− Thy1.2+)9 and inducible molecules including ST2 (IL1R1), Sca-1, 
CD278 (ICOS), CD25 (IL-2Rα), CD127 (IL-7Rα), CD117 (c-Kit), and IL-17RB 
(IL-25R)1, 10–12. Following activation, ILC2s produce IL-5 and IL-13 (as well as other 
cytokines), which mediate pulmonary eosinophilia, airway hyperreactivity1, 12, 13 and 
macrophage activation14. Although IL-33 in naive mouse lung is principally derived from 
structural cells15, hematopoietic cells (including macrophages) can express IL-33 
inducibly16, 17. Macrophages can activate ILC2s through an IL-33-dependent mechanism in 
a model of influenza-induced airway hyperreactivity10. Whether macrophages contribute to 
activating ILC2s in allergic inflammation in general, or in Alternaria-induced pulmonary 
inflammation in particular is not known.
Phospholipases A2 (PLA2) are a family of enzymes that release lysophospholipids and free 
fatty acids (FFAs) from membrane glycerophospholipids18, 19. While FFAs such as 
arachidonic acid (AA) can be converted to receptor-active eicosanoids (including 
prostaglandins and leukotrienes), other FFAs can act directly at cognate receptors to regulate 
metabolic processes and inflammatory responses20. PLA2s may have substrate preferences 
and specific cell and tissue expression, therefore serving context-specific functions. Group V 
PLA2 (Pla2g5) preferentially releases lysophosphatidylcholine (LPC) and the FFAs linoleic 
acid (LA) and oleic acid (OA)21–23, and is prevalently expressed by innate immune cells, 
including dendritic cells and macrophages24–26, as well as epithelial cells25–27. Using a 
mouse model of allergic lung inflammation induced by the allergens of house dust mite 
Dermatophagoides farinae, we found that Pla2g5 was necessary for the effector functions of 
both dendritic cells and macrophages24, 25. Adoptive transfer studies showed that Pla2g5 
expression by macrophages was required for their generation of CCL22 and recruitment of T 
cells into the lungs25. While the defects in cellular functions resulting from cell intrinsic 
absence of Pla2g5 suggest critical roles for endogenous lipids, neither the identity of the 
lipids nor their potential paracrine cellular targets are known.
Because eicosanoids may contribute to ILC2-mediated pulmonary inflammation9, 28, we 
hypothesized that Pla2g5-derived lipids generated from macrophages may contribute to 
ILC2 activation and subsequent pulmonary inflammation. Here we demonstrate that ILC2 
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activation is impaired in Pla2g5-null mice exposed to Alternaria. Moreover, adoptive 
transfers of macrophages restored ILC2 activation by a mechanism that is at least in part 
dependent on Pla2g5-dependent production of IL-33 and releases of LA, OA and AA by 
macrophages, which sustain ILC2 activation, and on Pla2g5-dependent expression of the 
LA-preferring FFA-receptor-1 (FFAR1) by ILC2s.
Results
Pulmonary inflammatory response to Alternaria requires Pla2g5
To investigate the role of Pla2g5 in activation of ILC2s, we used a model of allergic 
pulmonary inflammation induced by Alternaria, which relies on ILC2 activation to cause 
eosinophilic inflammation. We administered Alternaria (25μg/dose) every two days for four 
doses and lungs were collected 18h after the last dose1. Wt mice treated with Alternaria had 
significantly increased total lung cell numbers compared to Alternaria-treated Pla2g5-null 
mice (Figure 1A). The number of eosinophils (identified as CD45+/CD11c−/SiglecF+ 
cells)29 in Alternaria-treated Wt lungs was significantly higher than in Alternaria-treated 
Pla2g5-null lungs (Figure 1B). Alternaria-treated Wt mice had a significantly higher number 
of ILC2s, identified as CD45+, Lin−, Thy1.2+ cells9 (see Supplementary Figure 1A for 
staining controls), than equivalently treated Pla2g5-null mice (Figure 1C), although the 
percentages were similar (Figure 1C and data not shown). The expression of the inducible 
markers Sca-1, ST2, CD25, ICOS by lung ILC2s was drastically reduced in Alternaria-
treated Pla2g5-null mice compared to ILC2s isolated from equally treated Wt mice (Figure 
1D and Supplementary Figure 1B). The numbers (Figure 1E) and percentages 
(Supplementary Figure 1B and data not shown) of ILC2s expressing IL-5 or IL-13 were also 
significantly reduced in Pla2g5-null mice treated with Alternaria compared to Wt mice. 
Similar results were obtained by gating ILC2s as CD45+ Lin− Thy1.2+ Sca-1+ cells to 
exclude at least contaminating ILC330, 31 (Supplementary Figure 1C and data not shown). 
These data suggest that the absence of Pla2g5 affects both numbers and activation of lung 
ILC2s.
Induced IL-33 expression requires Pla2g5
Whereas IL-33 is constitutively expressed by lung barrier cells, its expression can also be 
upregulated during sustained inflammatory responses, in part reflecting the contributions 
from hematopoietic cells32. To investigate whether the reduced ILC2 activation in Pla2g5-
null mice was associated with a lack of either constitutive or inducible pools of IL-33, we 
measured IL-33 release into the BAL fluids of naive mice after administration of a single 
Alternaria dose. We also monitored the content of IL-33 in the lung at baseline and after 4 
doses of Alternaria using western blotting. We found that naive Wt and Pla2g5-null mice 
released similar amounts of IL-33 into BAL at 1 and 3h after Alternaria challenge (Figure 
2A), and showed equivalent amounts of immunoreactive IL-33 in lung lysates (Figure 2B). 
Only the full-length IL-33 was detected in the naive mice. After ten days and four doses of 
Alternaria, Wt lungs had increased amounts of IL-33 protein compared to naive mice, and 
both the preformed full-length form (34 kDa) and the proteolytically processed short length 
form (18kDa) were present. Compared with the Alternaria-treated Wt controls, the lungs of 
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Pla2g5-null mice showed sharply diminished induction of both the 18 and 34 kDa forms of 
IL-33 (Figure 2B).
To identify the cellular source(s) responsible for the constitutive and inducible pools of 
IL-33, we stained frozen sections of Wt and Pla2g5-null lungs with anti-IL-33. Since 
alveolar type 2 pneumocytes (AT2) are one of the major sources of IL-33 in Alternaria 
challenged mice15, we counterstained the lung sections with Abs against the AT2 cell 
marker surfactant protein C (SPC). Lungs of both Wt and Pla2g5-null mice showed IL-33 in 
the nuclei of SPC+ AT2 cells at baseline, with no differences between Wt and Pla2g5-null 
Alternaria challenged mice (Figure 2C). Since lung macrophages can also express IL-33 in a 
model of prolonged exposure to viral allergens10 and in the recovery phase of IAV 
infection33, we used intracellular staining and flow cytometry to determine whether 
macrophages contributed to the Alternaria-inducible pool of IL-33. Intracellular staining 
showed that Alternaria increased the number of CD68+/IL-33+ macrophages in Wt mice 
(Figure 2D). The number of CD68+/IL-33+ cells was significantly reduced in Alternaria-
treated Pla2g5-null mice. To determine whether cell-intrinsic Pla2g5 was involved in 
inducing IL-33 expression by macrophages, we examined IL-33 expression by Wt and 
Pla2g5-null BM-macrophages stimulated with GM-CSF, IL-4, and IL-3325, and also by lung 
macrophages enriched from Alternaria-treated Wt and Pla2g5-null mice using consecutive 
Percoll gradients25. Wt BM-macrophages activated to full potential by GM-CSF/IL-4/IL-33 
displayed robust induced expression of IL-33 mRNA compared to macrophages 
unstimulated or activated more weakly with GM-CSF/IL-4. In contrast, Pla2g5-null GM-
CSF/IL-4/IL-33 BM-macrophages showed significantly reduced induction compared to 
equally treated Wt controls (Figure 2E, left panel). Wt lung macrophages enriched from 
Alternaria-treated mice expressed significantly higher IL-33 mRNA compared to equally 
treated Pla2g5-null lung macrophages (Figure 2E, right panel).
Pla2g5-sufficient macrophages, but not IL-33 alone, can restore ILC2 activation and 
inflammation to Pla2g5-null mice
Next, we wanted to ascertain whether exogenous recombinant (r)-IL-33 would restore 
eosinophilia and ILC2 activation in Pla2g5-null mice. Administration of IL-33 over 10 days 
(100ng/dose, Figure 3, inset) robustly increased the numbers of eosinophils, ILC2s and 
Sca-1+ ILC2s in Wt mice3. Surprisingly, Pla2g5-null mice showed markedly diminished 
numbers of eosinophils, total ILC2s, and Sca-1+ ILC2s after treatment with IL-33 compared 
with Wt controls (Figure 3A). Exogenous IL-33 also induced substantial macrophage 
activation in Wt mice, as determined by the detection of resistin-like molecule alpha 
(RELMα) in macrophages. In contrast, macrophage activation was markedly impaired in 
IL-33-treated Pla2g5-null animals (Figure 3B). To determine whether the defect in ILC2 
function reflected the effects of ILC2-intrinsic Pla2g5, we sorted ILC2s from the lungs of 
Wt mice and performed qPCR. Pla2g5 transcripts were not detected in ILC2s (data not 
shown).
Because macrophages require endogenous Pla2g5 for their functions in pulmonary 
inflammation25, we wanted to investigate whether ILC2 activation and downstream lung 
inflammation could be restored to Pla2g5-null mice by reconstituting Pla2g5 function in 
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macrophages. We adoptively transferred unstimulated Wt BM-macrophages into Wt and 
Pla2g5-null recipient mice 24h before the second dose of Alternaria, then administered 3 
more doses and analyzed eosinophil numbers and ILC2 activation (Figure 4, inset). 
Compared to Pla2g5-null mice receiving Alternaria without macrophage transfer, Pla2g5-
null mice receiving Wt BM-macrophages plus Alternaria had significantly higher numbers 
of eosinophils and significantly higher numbers of ILC2s expressing Sca-1, CD25 or 
intracellular IL-5 (Figure 4A). In contrast, the transfer of Wt BM-macrophages into 
Alternaria-treated Wt mice did not significantly increase the recruitment of eosinophils or 
activation of ILC2s compared to Alternaria-treated Wt mice. Accordingly, transfers of 
Pla2g5-null macrophages into Pla2g5-null mice were ineffective (Figure 4A). However, 
transfers of Pla2g5-null macrophages in Wt mice (Figure 4A) significantly reduced the 
numbers of activated ILC2s expressing Sca-1, CD25, and IL-5 and eosinophil numbers, 
suggesting that Pla2g5-null macrophages could downregulate ILC2 activation when exposed 
to Th2 inflammatory environment. To further prove this point, we fully activated Pla2g5-null 
macrophages, and Wt macrophages as controls, with GM-CSF/IL-4/IL-33 and transferred 
them into Alternaria-treated Wt mice. As shown in Supplementary Figure 2, activated 
Pla2g5-null macrophages significantly reduced the numbers of IL-5+ILC2s and eosinophils 
in the lungs of Alternaria-challenged Wt mice. Transfers of Wt macrophages activated with 
GM-CSF/IL-4/IL-33 were ineffective.
Pla2g5-dependent generation of linoleic acid and oleic acid contribute to ILC2 activation 
and pulmonary inflammation
To identify candidate Pla2g5-derived mediators generated by macrophages that could 
contribute to ILC2 activation, we performed an unbiased assessment of lipids constitutively 
released by Wt and Pla2g5-null BM-macrophages, using mass spectrometry34. Compared to 
Wt BM-macrophages, Pla2g5-null BM-macrophages produced significantly lower quantities 
of medium- and long-chain FFAs, mostly represented by oleic acid (OA, 18:1), LA (18:2), 
and AA (20:4) (Figure 4B). Short chain FFAs were not different (data not shown). We also 
examined FFAs produced by lung macrophages enriched from Alternaria exposed mice by 
Percoll gradients, a technique previously shown to enrich lung macrophages >80%25. We 
did not sort CD68+ cells because staining for CD68 requires fixation with paraformaldehyde 
and permeabilization with saponin (as in Figure 2D) which could alter the lipid composition 
of the cells. Compared to Wt lung macrophages, Pla2g5-null macrophages had reduced 
quantities of OA, and LA (Figure 5A). AA was similar in both genotypes.
To determine whether LA and/or OA could restore the IL-33-mediated induction of 
eosinophilic inflammation and ILC2 expansion, we administered intranasal LA and/or OA, 
alone and in combination with IL-33 (4 doses in 10 days), to Wt and Pla2g5-null mice. 
Neither LA nor OA alone caused pulmonary inflammation in either genotype (Figure 5B). 
The combination of LA + IL-33 increased the numbers of eosinophils in the lungs of Wt 
mice by ~3-fold when compared to IL-33 alone, and the combination of LA and OA + IL-33 
further increased the numbers of eosinophils in this genotype (Figure 5B). In contrast, LA 
failed to potentiate IL-33-induced eosinophilia in Pla2g5-null mice, although OA + IL-33 
was markedly active and the combination of LA and OA + IL-33 induced a modest further 
increase over IL-33 + OA. The effects of FFAs on the numbers of lung ILC2s expressing 
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IL-5 paralleled their effects on eosinophil numbers (Figure 5C and Supplementary Figure 3 
for representative FACS plots), although the numbers of IL5+ILC2s in IL-33+LA+OA 
treated Pla2g5-null mice were slightly lower than in equally treated Wt mice.
Because AA-derived eicosanoids were previously shown to contribute to ILC2 
activation9, 28, to understand whether AA could increase the numbers of IL5+ ILC2s in FFAs 
treated Pla2g5-null mice to the same levels as equally treated Wt mice, in another set of 
experiments, we administered AA alone or in combination with IL-33+LA+OA to Wt and 
Pla2g5-null mice. AA alone did not induce pulmonary inflammation in either genotype 
(Figure 5D and E). In combination with IL-33, AA induced in Wt mice a 2-fold increase in 
eosinophil numbers (Figure 5D) and IL5+ILC2s (Figure 5E), but was ineffective in Pla2g5-
null mice. The combination of IL-33+LA+OA+AA induced in Wt mice a significant 
increase in numbers of eosinophils and IL-5+ILC2s compared to IL-33-esposed mice (Figure 
5D and E) and a nearly significant increase in Pla2g5-null mice. However, in both genotypes 
the effects of IL-33+LA+OA+AA were similar to those of IL-33+LA+OA (Figure 5B–E).
To determine whether LA and/or OA directly activated ILC2s, we sorted ILC2s from lungs 
of Alternaria-treated Wt and Pla2g5-null mice, rested them for 40h, and stimulated with LA, 
OA, IL-33 or a combination for 8h. Then we assayed ILC2s for their expression of 
intracellular IL-5. Staining controls and representative FACS plots are shown in 
Supplementary Figure 4. IL-33 significantly increased the percentage of IL-5-expressing 
ILC2s isolated from both Pla2g5-null and Wt mouse lungs. Neither LA nor OA induced 
significant IL-5 expression by ILC2s of either genotype. LA, but not OA, significantly 
potentiated IL-33-induced expression of IL-5 by Wt ILC2s, and the combination of LA + 
OA did not differ from the effects of LA (Figure 6A). In contrast LA suppressed the IL-33-
induced increase in percentages of IL-5+ Pla2g5-null ILC2s (Figure 6B). OA was inactive. 
To determine whether LA and OA amplified the release of IL-5 by Wt ILC2s, we measured 
the quantity of secreted IL-5 from sorted lung ILC2s activated ex vivo (Figure 6C). IL-33 
induced the release of large quantities of IL-5 in supernatant of sorted Wt ILC2s and the 
combination of IL-33+LA+OA significantly potentiated this release. In contrast, Pla2g5-null 
ILC2s released significantly less amount of IL-5 and failed to exhibit potentiation in 
response to LA+OA (Figure 6C).
Medium and long chain FFAs signal through two G protein-coupled receptors, FFA 
receptor-1 (FFAR1) and FFA receptor-4 (FFAR4)35–39. To determine whether ILC2s 
expressed these receptors, and to determine the potential basis for the different responses of 
Wt and Pla2g5-null ILC2s to LA, we analyzed ILC2 expression of FFAR1 and FFAR4 in 
ILC2s sorted from Wt and Pla2g5-null Alternaria-treated mice. Wt ILC2s expressed FFAR1 
mRNA and its expression was significantly higher compared to Pla2g5-null ILC2s (Figure 
6D). Wt and Pla2g5-null ILC2s also expressed FFAR4 mRNA to similar extents (Figure 
6D).
Discussion
It is now well established that ILC2s are key effectors of pulmonary inflammation. Their 
contribution is particularly evident in models triggered by the release of alarmins (IL-33, 
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IL-25, TSLP) from epithelial cells2, 4, 9, 11, 40, 41 in response to environmental proteases11, 
many of which are relevant to asthma in humans13. IL-33, alone and in combination with 
IL-25, TSLP, and other cytokines can directly induce IL-5, IL-13, and IL-9 generation from 
ILC2s, promoting eosinophilic inflammation and goblet cell metaplasia that can occur 
independently of or in concert with adaptive immunity. The Alternaria model of pulmonary 
inflammation has been particularly useful to establish the contribution of innate, epithelial-
derived alarmins and their downstream effects on ILC2 activation and subsequent 
development of airway inflammation1, 3. While macrophages can also express IL-3342, and 
other innate cell types have been proposed to interact with ILC2s43, no previous studies had 
established whether macrophages can activate ILC2s in Alternaria-induced pulmonary 
inflammation and which mediators might be involved. Pla2g5-null mice show markedly 
impaired type 2 pulmonary inflammation that reflects, at least in part, a requirement for cell-
intrinsic Pla2g5 for macrophage effector functions25, 26. We therefore investigated the role 
of Pla2g5 in general and macrophage-associated Pla2g5 in particular, in lipid-generating 
function and its potential downstream effects on ILC2 activation in a model of pulmonary 
inflammation induced by Alternaria.
We subjected Wt and Pla2g5-null mice to a protocol involving the administration of 
Alternaria four times over a 10-day period, which elicits prominent contributions from IL-33 
and ILC2s. The marked pulmonary eosinophilia and increases in the numbers of total and 
activated ILC2s observed in Wt mice (Figure 1) were all sharply reduced in Pla2g5-null 
mice. The reduced levels of both eosinophils and ILC2s were paralleled by reduced levels of 
IL-33 induction (Figure 2B), but not constitutively levels of IL-33 (Figure 2B), or by release 
of IL-33 in response to a single Alternaria dose (Figure 2A). AT2 cells are the dominant 
source of pre-formed IL-33 in the mouse lung, as well as of the pre-formed IL-33 in 
response to a single dose of Alternaria15. In our study, AT2 cells showed equivalent staining 
for IL-33 in Wt and Pla2g5-null mice (Figure 2C), suggesting that Pla2g5 functions are not 
required by AT2 to store or release IL-33. In marked contrast, IL-33 expression by lung 
macrophages was substantially induced in Alternaria-treated Wt mice but not in Pla2g5-null 
mice (Figure 2D), suggesting that macrophages may be one of the cell types accounting for 
the impaired induction of IL-33 in Pla2g5-null lungs. Our previous studies demonstrated that 
macrophage-intrinsic Pla2g5 was necessary for inducible expression of Th2 cell-active 
chemokines25. Our current results, supported by our ex vivo data (Figure 2E), suggest that 
this may also be the case for IL-33 induction.
When administered exogenously to naive Wt mice, r-IL-33 is sufficient alone to drive a 
robust type 2 inflammatory response that depends on ILC2s3, 40. Despite the evident role of 
Pla2g5 in IL-33 induction by macrophages, the direct administration of IL-33 to naive 
Pla2g5-null mice was insufficient to induce inflammation, ILC2 expansion, and macrophage 
activation (Figure 3). Combined with the fact that transfer of Wt macrophages almost fully 
restored these parameters in Pla2g5-null mice in response to Alternaria challenges (Figure 
4A), we suspected the involvement of additional Pla2g5-dependent factors that could enable 
macrophages to activate ILC2s, alone or in concert with IL-33. We identified at least two 
candidate FFAs (LA and OA) as Pla2g5-dependent factors derived from BM and lung 
macrophages (Figure 4B and 5A). Both of these FFAs can signal to immune and non-
immune cells through the GPCRs FFAR1 and FFAR4, although their potential roles as 
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mediators of allergic inflammation in general and stimulants of ILC2 activation in particular 
had not been explored. The sharp potentiation of IL-33-driven eosinophilic inflammation 
and ILC2 expansion in Wt mice by LA, alone and in combination with OA (Figure 5B and 
C), was parallel by its effects on IL-33-induced IL-5 generation (Figure 6A) and secretion 
(Figure 6C) by ILC2s ex vivo. Interestingly in Pla2g5-null mice this LA-induced 
potentiation of inflammation in vivo (Figure 5A and B) and ex vivo (Figure 6B and C) was 
absent. The lack of LA responsiveness by Pla2g5-null ILC2s is consistent with the lack of 
ILC2-intrinsic expression of FFAR1 (Figure 6D), which exhibits a preference for LA over to 
OA44. Notably, although unable to directly activate Wt or Pla2g5-null ILC2s, OA did 
substantially enhance IL-33-induced eosinophilic inflammation and expand lung ILC2s in 
Pla2g5-null mice, reflecting a potential compensatory mechanism involving ILC2 activation 
by a yet to-be-determined OA-responsive cell. Since FFAR1 and FFAR4 are broadly 
expressed by immune and non-immune cell types45, it is likely that Pla2g5-derived FFAs 
potentiate innate type 2 immune responses and ILC2 activation by both direct and indirect 
pathways. We speculate that ILC2s require conditioning in vivo by one or more inductive 
factors that are deficient in Pla2g5-null mice in order to express FFAR1 and respond to LA. 
Moreover, the fact that FFAs including AA could not restore ILC2 activation in Pla2g5-null 
mice to the levels of equally treated Wt mice (Figure 5C and E), suggests that the presence 
of Pla2g5-null macrophages (Figure 4A and Supplementary Figure 2) through a yet 
unknown mechanism might limit ILC2 activation in Pla2g5-null mice.
Our data clearly identify a role for macrophages, and Pla2g5-derived FFAs, as activators of 
ILC2s, acting in concert with IL-33. It is likely that the coordinate action of ILC2s, 
macrophages and epithelial cells induces pulmonary inflammation, highlighting a complex 
interplay of innate cells in the lung4, 12, 46. These data also suggest that FFAs directly 
activate ILC2s through FFAR1, which is expressed on ILC2s in a yet to be identified 
Pla2g5-dependent fashion. However, it is likely that additional Pla2g5-generated factors 
might regulate type 2 immunity. Thus, our observations suggest that macrophage-derived 
FFAs amplify innate, IL-33-triggered type 2 immunopathology in diseases such as asthma. 
We speculate that LA, derived at least in part from Pla2g5-expressing macrophages, may 
contribute to the function of ILC2s in other circumstances, such as homeostasis of adipose 
tissue and glucose metabolism where macrophages, Pla2g5, IL-33, and ILC2s have all been 
implicated22, 47.
Methods
Lung inflammation
C57/BL6 Wt and Pla2g5-null mice48, 49 (9–12 wk-old males) received 25 μg of Alternaria 
alternata extract (Greer Laboratories, Lenoir, NC) in 20 uL of PBS or PBS alone intranasally 
(i.n.) on days 0,3,6 and 9 and euthanized 18h later1 or a single dose of 100 μg and were 
euthanized after 1h or 3h2. Alternatively, Wt and Pla2g5-null naïve mice were given mouse 
rIL-33 (R&D Systems, Minneapolis, MN) i.n. 100 ng/dose on days 0,3,6 and 9 with or 
without LA (132 nM)28 OA (106 nM) or AA (99 nM), and mice were euthanized 18h after 
the last dose. All animal experiments were approved by the Animal Care and Use 
Committee of the Dana-Farber Cancer Institute (Boston, MA).
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Flow cytometry
Lungs were manually chopped to approximately 10mm pieces, then digested in RPMI 
containing 428 U/ml Collagenase IV (Worthington, Lakewood, NJ) and 20 mg/ml DNAse I 
(Roche, Mannheim, Germany) (30min, 37°C). After red cell lysis, the obtained cell 
suspension from single mouse was washed and counted. Cells were blocked (1h, 4 °C) with 
1% of rat anti mouse CD16/CD32 (BD Biosciences, San Jose, CA) and 10% donkey serum 
and then stained (1h, 4 °C) with appropriate Abs: CD45 PercPCy5 (clone 30-F11, 
BioLegend, San Diego, CA), CD19 FITC (6D5, Biolegend), CD3 FITC (145-2C11, 
BioLegend), CD11b FITC (M1/70, BioLegend), CD11c PE-Cy7 FITC (N418, BioLegend), 
Ly6G/C FITC (RB6-8C5, eBiosciences), Nk1.1 FITC (PK136, Biolegend), FcεR1 FITC 
(MAR-1, Biolegend), Siglec-F PE (E50-2440, BD Bioscience), Thy 1.2 APC (53–2.1, 
eBioscience, San Diego, Ca), ICOS (C398.4A, eBiosciences), Sca-1 (D7, eBioscieces), 
CD25 (PC61, eBiosciences), ST2 biotin (clone DJ8, MD Bioscience) followed by PE 
streptavidin (eBiosciences). In selected experiments cells were fixed with 4% 
paraformaldehyde (7 min, 21°C), washed, permeabilized with 0.1% saponin (SigmaAldrich, 
St Louis, Ca) (7 min, 21°C) and stained with CD68 APC (FA-11, AbD Serotec, Raleigh, 
Nc), IL-5 PE (TRFK5, Biolegend), IL-13 (eBio13A eBiosciences), IL-33 PE (396118, R&D 
Systems, Minneapolis, MN), rabbit polyclonal anti murine RELM-α (Peprotech, Rocky Hill 
NJ)) and corresponding isotypes as controls. Alternatively, cells were permeabilized with 
BD Cytofix/Cytoperm kit (BD Biosciences, San Jose, CA). The acquisition was performed 
on a FACSCanto flow cytometer with FACSDiva software (BD Biosciences), and data were 
analyzed with FlowJo (Tree Star, Ashland, OR).
Airways analysis and lung cell processing
Bronchoalveolar lavage (BAL) was performed with 0.7 mL PBS (Sigma-Aldrich) containing 
0.5 mM EDTA (three times). The BAL fluid was collected, and cell-free supernatant was 
aliquoted and frozen. ELISA was used to measure IL-33 (R&D Systems). In selected 
experiments lung macrophages were enriched by Percoll gradients25 of lung homogenates 
pulled from 3–4 Alternaria-treated Wt or Pla2g5-null mice. Cells were then counted and 
assayed by qPCR or Mass Spectrometry.
Western Blot
Right lungs were collected at the time of euthanasia and snap frozen. Proteins were isolated 
from tissue homogenates in RIPA buffer (Boston Bioproducts, Ashland, MA, USA) with 
protease inhibitors26. The protein concentration in cell lysates was measured using the BCA 
Assay (Pierce, Thermo Scientific). 20 μg of proteins were separated on a 10–20% Tris-
Glycine gel (Novex, Life Technologies) and transferred to a PVDF membrane. After 
blocking overnight at 4°C in 5% milk, blots were incubated with a goat polyclonal IL-33 
(1:500, R&D Systems) or mouse monoclonal β-actin (1:1000, Cell Signaling, Danvers, MA) 
antibodies diluted in TBST at RT for 2h, followed by a rabbit anti-goat or goat anti-mouse 
secondary antibody (1:3000, BioRad) diluted in TBST for 1h at RT. The blots were 
visualized using the Supersignal West Femto Chemiluminescent substrate (Thermo 
Scientific) and imaged by a KODAK M35A X-OMAT processor.
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Frozen sections
Lungs of Wt and Pla2g5-null mice were excised and immersed in RPMI. Within 1h of 
surgery, the tissue was removed from RPMI and fixed in 4% paraformaldehyde, then 
embedded in Tissue-Tek® O.C.T.™ Compound (Sakura Finetek), and kept at −80°C until 
sectioning. Sections of 5-μm thickness were freshly cut, thaw-mounted onto slides, and 
stained for confocal microscopy. Frozen sections were rehydrated for 1h at RT then blocked 
with 10% donkey serum, followed by incubation with goat polyclonal IL-33 (AF3626, R&D 
Systems) and rabbit polyclonal proSPC (AB3786, Millipore, Temecula, CA) antibodies or 
appropriate isotypes controls at 4°C, overnight. Samples were washed, incubated at RT for 
1h with appropriate secondary antibodies, washed and covered with Fluoroshield mounting 
media (Electron Microscopy Sciences, Hatfield, PA). Sections were imaged using a Nikon 
C1 plus laser scanner confocal system with a 40× oil Plan-Fluor NA1.3 objective lens. 8–10 
Z-stack images of 0.5 μm were acquired through a small pinhole using Nikon EZ-C1 
software. Images were analyzed using Image J (U.S. National Institute of Health, Bethesda, 
MD).
BM macrophage transfer
Wt or Pla2g5-null bone marrow (BM) cells were collected from femurs and tibiae of mice. 
The disaggregated cells were counted and suspended in complete medium (DMEM F12, 
5%FBS, 100U/ml penicillin, 100ug/ml streptomycin, 0.1mM nonessential amino acids, 
2mM L-glutamine and 0.05 μM 2-ME) containing 50ng/ml murine r-MCSF (PeproTech) at a 
concentration of 4.0 ×106 cells/ml in a 10ml/Petri dish. On day 3, 10 ml of medium 
containing r-MCSF were added to each dish. On day 7, cells were harvested with PBS 
containing Lidocaine (4mg/ml, 15min, 37C) and resuspended at concentration of 5×106 
cells/ml in PBS. For adoptive transfer, 1 ×105 Wt or Pla2g5-null BM-macrophages were 
transferred i.t. into Wt and Pla2g5-null mice two days after the first dose of Alternaria 
followed by 3 more doses of Alternaria (25 μg in 20 μl PBS) i.n. on day 3, 6 and 9. Mice 
were euthanized 18h after the last dose.
Mass Spectrometry of lipids
Wt and Pla2g5-null BM-macrophages were cultured for 7 days in r-MCSF. Adherent cells 
were collected, frozen and shipped for analysis by mass spectrometry. In another set of 
experiments lung macrophages were enriched by multiple Percoll gradients25. Free fatty 
acid analysis was performed according to a previously published method34, 50. Briefly, the 
cell pellet was homogenized in 500 ul of PBS/10% methanol. An aliquot of 200 μl 
corresponding to about 0.5×106 cells was withdrawn and a cocktail of internal standards 
consisting of 15 deuterated fatty acids was added. The extraction was initiated with 500 μl of 
methanol and 25 μl of 1N HCl and a bi-phasic solution is formed by addition of 1.5 ml of 
isooctane. The phases are separated by centrifugation and the isooctane phase containing the 
free fatty acids FFA fraction was removed. The extraction is repeated once and the combined 
extracts are evaporated to dryness. The free fatty acids were derivatized with 
pentafluorobenzyl (PFB) bromide and the resulting fatty acid PFB esters were analyzed by 
gas chromatography/mass spectrometry using a negative chemical ionization mode (Agilent 
6890N gas chromatograph equipped with an Agilent 5973 mass selective detector; Agilent, 
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Santa Clara, CA). Standard curves for each of the fatty acids were acquired in parallel using 
identical conditions. The quantitative assessment of fatty acids in a sample was achieved by 
comparison of the mass spectrometric ion signal of the target molecule normalized to the 
internal standard with the matching standard curve according to the isotope dilution method 
and by protein content34.
ILC2 cells sorting and culture
Wt and Pla2g5-null mice received four doses of 25ug of Alternaria in 20ul of PBS i.n. on 
day 0, 3, 6 and 9 and euthanized 18h later in order to expand ILC2s prior to FACs sorting. 
Sorting of ILC2s (CD45+ Lin− (CD3, CD19, Ly6g, CD11c, CD11b, Nk1.1, FcεR1−), 
Thy1.2+) was performed using a FACSDiva 8.0.1 cell sorter (BD Bioscience). Purified 
CD45+ lin-Thy1.2+ cells (>98%) were rested for 40h with 10ng/mL rIL-2 and rIL-7 (R&D 
Systems, Minneapolis, MN) in 96 well around bottom plates (20000 cells per well). Prior to 
stimulation, the medium was changed to fresh medium. ILC2s were cultured with 30ng/mL 
rIL-33 (R&D Systems), 200 μM Linoleic Acid (Cayman Chemical) or 200 μM Oleic Acid 
(Cayman Chemical)22 or all together for 8h. For intracellular cytokine staining, 1 μl/mL of 
Golgi Plug (BD Bioscience) was added to ILC2s 6h before collection for FACs analysis.
ELISA
Wt and Pla2g5-null mice sorted ILC2s were obtained as described above and rested for 40h 
with 10ng/mL rIL-2 and rIL-7 in a 96 well round bottom plates (40000 cells per well). After 
changing to fresh media, ILC2s were stimulated with 30ng/mL rIL-33 or 30ng/mL rIL-33, 
200 μM Linoleic Acid, 200 μM Oleic Acid for 8h. Supernatants were then collected. IL-5 
ELISA (R&D Systems, M5000) was performed as per manufacturer protocol. For these 
experiments, during lung homogenization, Dispase (Gibco, Life Technologies, NY) was 
added (2U/ml) to increase the yield for ILC2s.
Real-time PCR
Total RNA was isolated from lysate with the RNeasy Micro Kit (Qiagen, Louisville, KY, 
USA), reverse transcribed into cDNA (High-Capacity cDNA Reverse Transcription Kit; 
Thermo science-Applied Biosystems, Foster City, CA, USA) and measured by real-time 
PCR with the use of SYBR Green/ROX master mix (SABiosciences, Frederick, MD, USA) 
on an Mx3005P thermal cycler (Stratagene, Santa Clara, CA, USA). The ratio of each 
mRNA relative to the GAPDH mRNA was calculated with the Ct threshold cycle method. 
The mouse primers used were GAPDH F: TCAACAGCAACTCCCACTCTTCCA; R: 
ACCCTGTTGCTGTAGCCGTATTCA. Pla2g5 F: TGGTTCCTGGCTTGCAGTGTG; R: 
TTCGCAGATGACTAGGCCATT. IL-33 F: TCCCAACAGAAGACCAAAG; R: 5′-
GATACTGCCAAGCAAGGAT. FFAR1/GPR40 and FFAR4/GPR120 were from Qiagen. 
Real-time PCR products were run on a 1.5% agarose gel and visualized using chemilmager 
4400 fluorscience system (Alpha Innotech, Missouri, TEX, USA)
Statistical analysis
Comparisons between 2 groups were made by using unpaired Student’s t-test. To compare 
three or more groups, we performed One-way ANOVA or Two-Way ANOVA with Sidak’s 
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correction for multiple comparisons. Comparisons were performed with Prism software 
(GraphPad, La Jolla, CA). Data are expressed as mean ± SEM, and P<0.05 was considered 
significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Alternaria-induced pulmonary inflammation requires Pla2g5
(A) Total cells counts from homogenate lungs of naive and Alternaria-treated Wt and 
Pla2g5-null mice. Analysis by flow cytometry of lung cell from naive and Alternaria-treated 
Wt and Pla2g5-null lung homogenates of (B) eosinophils gated as CD45+ CD11c− SiglecF+; 
(C) ILC2s gated as CD45+ Lin− Thy1.2+; (D) histograms of Sca-1, ST2, ICOS, CD25 gated 
on Thy1.2+ cells (isotype in gray, Wt in blue, Pla2g5-null in red), and (E) expression of 
intracellular IL-5 and IL-13 by Thy1.2+ ILC2s. Values are mean ± SEM of at least three 
independent experiments with 5–9 (naïve) or 10–21 (Alternaria-treated) mice per group. 
Images are from one representative mouse per group. *** P< 0.0005, **P< 0.005, *P< 0.05.
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Figure 2. Induced IL-33 generation in the lung requires Pla2g5
(A) IL-33 levels determined by ELISA of BAL 1 or 3 h after Alternaria administration in Wt 
and Pla2g5-null mice. (B) Expression of IL-33 protein by Western blot in homogenized 
lungs of naive and Alternaria-treated Wt and Pla2g5-null mice treated with Alternaria for 10 
days (4 doses). Equivalent loading was confirmed by immunoblot analysis for β-actin. (C) 
Frozen sections from the lungs of Wt and Pla2g5-null mice naive or treated with Alternaria 
for 10 days, were stained for IL-33 (red), SPC (green) and nuclei (blue). Original 
magnification ×40. Size bar 50 μm. (D) Expression of IL-33 on gated CD68+ lung cells of 
naive and Alternaria-treated Wt and Pla2g5-null mice evaluated by flow cytometry. (E) 
Expression of IL-33 mRNA relative to GAPDH measured by qPCR in BM-macrophages 
unstimulated or stimulated with GM-CSF/IL-33/IL-4 or lung macrophages enriched by 
Percoll density gradients from 5–8 pulled lung homogenates of Alternaria-treated mice. 
Values are mean ± SEM from two or three independent experiments assayed in duplicate (E) 
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or with 5–8 mice per group (A and D). (B and C) Images and panels are from one 
experiment representative of two with similar results. **P< 0.005, *P< 0.05.
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Figure 3. r-IL-33 induces pulmonary inflammation in Wt but not in Pla2g5-null mice
Flow cytometry analysis of (A) eosinophils, Thy1.2+ ILC2s and Thy1.2+ ILC2s expressing 
Sca-1, (B) Relm-α expression on gated CD45+CD11c+ cells from homogenate lungs of Wt 
and Pla2g5-null mice naive or administered r-IL-33 for 10 days. Values are mean ± SEM of 
two (B) or three (A) independent experiments with 7–15 mice per group. **P< 0.005, *P< 
0.05.
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Figure 4. Transfers of Wt and Pla2g5-null BM-macrophages regulate Alternaria-induced 
pulmonary inflammation
A) Pla2g5-null and Wt recipient mice received Wt (medium grey bars) or Pla2g5-null (dark 
gray bars) BM-macrophages intratracheally at day 2, followed by Alternaria i.n. at day 3, 6 
and 9 or only Alternaria (light grey bars). Mice were euthanized 18 h after the last dose. 
Analysis by flow cytometry of eosinophils gated as CD45+ CD11c− SiglecF+ lung cells and 
expression of CD25, Sca-1 and intracellular IL-5 on Thy1.2+ ILC2s. B) Production of FFAs 
measured by mass spectrometry in Wt and Pla2g5-null BM-Macrophages. (A) Values are 
mean ± SEM of 2 independent experiments with 10–12 mice per group. (B) Data are from 3 
independent experiments. # P<0.0001, *** P<0.0005, **P< 0.005, *P< 0.05.
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Figure 5. Intranasal administration of LA and OA in combination with r-IL-33 increased 
eosinophilia and ILC2 activation in Wt and Pla2g5-null mice
(A) Production of FFAs measured by mass spectrometry in Wt and Pla2g5-null lung 
macrophages enriched by Percoll gradients of lung homogenates pulled from 5–8 mice. 
Flow cytometry analysis of (B, D) numbers of eosinophils and (C, E) Thy1.2+ ILC2s 
expressing intracellular IL-5 in homogenate lungs of Wt (black bars) and Pla2g5-null mice 
(white bars) treated i.n. with IL-33, LA or OA (B, C), or IL-33, LA, OA and AA (D, E) as 
indicated. Values are mean ± SEM of two independent experiments with 5 samples (A), two-
four independent experiments (B, C, D) or one representative experiment (E) with 4–12 
mice per group, and were compared by t-test (A) or One-way ANOVA with Sidak’s 
correction for multiple comparisons. **P< 0.005, *P< 0.05.
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Figure 6. Differential LA- and OA-induced activation of sorted Wt and Pla2g5-null ILC2s and 
FFAR1 expression
ILC2s were expanded in-vivo by 4 Alternaria challenges for 10 days. CD45+ lin-, Thy1.2+ 
cells were FACS sorted from 3–4 pulled lung homogenates, and rested for 40 hours prior to 
in-vitro stimulation with LA (200 μM), OA (200 μM), IL-33 (30ng/ml) or all together for 8 
hours then analyzed by flow cytometry for percentage of IL-5 positive Wt (A) and Pla2g5-
null (B) ILC2s. Unstimulated cells were used as controls. (C) IL-5 levels were measured by 
ELISA in the supernatants of sorted Wt and Pla2g5-null Thy1.2+ ILC2s stimulated as 
indicated. (D) Expression of FFAR1 and FFAR4 mRNA relative to GAPDH measured by 
qPCR in sorted ILC2s from Alternaria-treated Wt and Pla2g5-null mice. Data are from at 
least 3 independent experiments. Values are expressed as means ± SEM and were compared 
by One-way ANOVA (A–B), Two-way ANOVA (C) with Sidak’s correction for multiple 
comparisons, or t-test (D). ****P< 0.0001, *** P<0.0005, **P<0.005, *P< 0.05, # P<0.05 
vs. IL-33 alone.
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